anti-BCMA/CD70-CAR-T cells
Phase 1Cell therapy
anti-BCMA/CD70-CAR-T cells is one of 28 biologic programs targeting CAR T Cell Therapy. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Refractory
#DrugCompanyPhaseTrials
1Nplate
AmgenPhase 3
Jakafi
IncytePhase 2
Blincyto
AmgenPhase 1
Gecacitinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Maat013
MMaaT Pharma
Phase 3
Tavalisse
RRigel Pharmaceuticals
Phase 1
MB-CART19.1
MMiltenyi Biomedicine GmbH
Phase 2
Flomax
SanofiPreclinical
CD19 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 1
CAR-T Therapy
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CAR T Cell Therapy1 trial
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06553898·18 enrolled
Refractory1 trial
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06934447·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-BCMA/CD70-CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details